CELEX: 62022TN0165
Language: en
Date: 2022-03-29 00:00:00
Title: Case T-165/22: Action brought on 29 March 2022 — Saure v Commission

16.5.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 198/64
            
         
      Action brought on 29 March 2022 — Saure v Commission
      (Case T-165/22)
      (2022/C 198/92)
      Language of the case: German
      
         Parties
      
      
         Applicant: Hans-Wilhelm Saure (Berlin, Germany) (represented by: C. Partsch, lawyer)
      
         Defendant: European Commission
      
         Form of order sought
      
      The applicant claims that the Court should:
      
                  —
               
               
                  annul the Commission’s decision of 7 February 2022 to reject the applicant’s request for access to documents of the Commission by refusing to provide him with copies of all of the correspondence that it has exchanged, since 1 April 2020, with the company AstraZeneca plc or with its subsidiaries as well as with the Federal Chancellery of Germany or with the Federal Ministry of Health, relating to the company AstraZeneca plc or its subsidiaries, and in particular to the quantity of Covid-19 vaccines offered by AstraZeneca plc and its delivery deadlines;
               
            
                  —
               
               
                  order the defendant to pay the costs of the proceedings.
               
            
         Pleas in law and main arguments
      
      In support of the action, the applicant relies on four pleas in law.
      
                  1.
               
               
                  First plea in law: The applicant has a right to access the European Commission documents at issue pursuant to Article 2(1) of Regulation (EC) No 1049/2001. (1) The refusal by the Commission infringes that provision.
               
            
                  2.
               
               
                  Second plea in law: The ground for exclusion laid down in the second indent of Article 4(2) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. That ground for exclusion is limited in time and applies only to pending court proceedings and legal advice. The proceedings pending in Belgium against AstraZeneca under No 2021/48/C relate to a substantially different set of facts and have already been disposed of by the judgment of 18 June 2021.
               
            
                  3.
               
               
                  Third plea in law: The ground for exclusion laid down in Article 4(1)(b) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. The public interest in the disclosure of personal data prevails.
               
            
                  4.
               
               
                  Fourth plea in law: The ground for exclusion laid down in the first indent of Article 4(2) of Regulation (EC) No 1049/2001 does not preclude the applicant’s right of access. The requested information does not contain any trade secrets within the meaning of Article 2 of Directive (EU) 2016/943, (2) as it is known and there have been no reasonable steps to keep it secret.
               
            
         (1)  Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43).
      
         (2)  Directive (EU) 2016/943 of the European Parliament and of the Council of 8 June 2016 on the protection of undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use and disclosure (OJ 2016 L 157, p. 1).